PharmaDepth

Company profile

REGENERON PHARMACEUTICALS, INC.

NASDAQ:REGNBiotechnology: Pharmaceutical Preparations

Drug pipeline (42)

AssetStageRevenueTrialsStatus
Afliberceptapproved—11approved
ALIROCUMABapproved—16approved
ATOLTIVIMABapproved—0—
DUPILUMABapproved—43approved
Lunsotogene Parvecapproved—1approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (352)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT06452771phase1active_not_recruiting2024-06-272026-12-04Regeneron PharmaceuticalsA First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
NCT07526116phase1recruiting2026-06-052027-02-08Regeneron PharmaceuticalsA First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults
NCT06413680phase1_2recruiting2024-09-232030-02-03Regeneron PharmaceuticalsA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT07187401phase1_2recruiting2026-02-112029-11-29Regeneron PharmaceuticalsA First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
NCT00871559phase1completed2009-06-012014-02-01Regeneron PharmaceuticalsA Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

FDA applications (11)

ApplicationTypeApplicantProducts
BLA 125387BLARegeneron Pharmaceuticals, Inc.
BLA 125559BLARegeneron Pharmaceuticals, Inc.
BLA 125874BLARegeneron Pharmaceuticals, Inc.
BLA 761055BLARegeneron Pharmaceuticals, Inc.
BLA 761097BLARegeneron Pharmaceuticals, Inc.